IMI – Clinical Management Guidelines Report

Best practice clinical guidelines for myopia control involve an understanding of the epidemiology of myopia, risk factors, visual environment interventions, and optical and pharmacologic treatments, as well as skills to translate the risks and benefits of a given myopia control treatment into lay language for both the patient and their parent or caregiver. This report details evidence-based best practice management of the pre-, stable, and the progressing myope, including risk factor identification, examination, selection of treatment strategies, and guidelines for ongoing management. Practitioner considerations such as informed consent, prescribing off-label treatment, and guides for patient and parent communication are detailed. The future research directions of myopia interventions and treatments are discussed, along with the provision of clinical references, resources, and recommendations for continuing professional education in this growing area of clinical practice

Update and guidance on management of myopia. European Society of Ophthalmology in cooperation with International Myopia Institute

The prevalence of myopia is increasing extensively worldwide. The number of people with myopia in 2020 is predicted to be 2.6 billion globally, which is expected to rise up to 4.9 billion by 2050, unless preventive actions and interventions are taken. The number of individuals with high myopia is also increasing substantially and pathological myopia is predicted to become the most common cause of irreversible vision impairment and blindness worldwide and also in Europe. These prevalence estimates indicate the importance of reducing the burden of myopia by means of myopia control interventions to prevent myopia onset and to slow down myopia progression. Due to the urgency of the situation, the European Society of Ophthalmology decided to publish this update of the current information and guidance on management of myopia. The pathogenesis and genetics of myopia are also summarized and epidemiology, risk factors, preventive and treatment options are discussed in details

PARTICLE SIZE EXPERIMENTS ON THE ADSORPTION OF PB(II) FROM POLLUTED WATER BY RICE STRAW

Particle Size Experiments on the Adsorption of Pb (II) from Polluted Water by Rice Straw. As rice straw is abundantly available in Indonesia and other tropical developing countries as an agricultural waste. This material may be used as a simple and environmentally friendly alternative to remove heavy metals from contaminated water sources for human use. In this paper the effect of particle size of rice straw in adsorbing Pb (II) is studied. The Pb (II) adsorbed by straw is build up in the increasing of Pb concentration in the solution and it reached an optimum at a certain point, which showed that there is a limit in the active sites. At lower initial concentrations of Pb (II) solutions particle size of straw cause much variation in the adsorption of Pb, while surprisingly at increasing initial concentration, bigger particle shows higher adsorption capacity. This study showed that the adsorptive power of rice straw for Pb is independent of particle size

Power to methane: WP 2/3: a promising new method for hydrogen delivery to methanogens results in more methane from biomass

Excess of renewable electricity from wind turbines or solar panels is used for electrolysis of water. To store this renewable energy as methane, the hydrogen is fed to an anaerobic digester to stimulate biological methanation by hydrogenotrophic methanogens. This workpackage focusses on the best ways for hydrogen delivery and the community changes in a biomethanation reactor as a result of hydrogen supply

Farm-scale bio-power-to-methane: Comparative analyses of economic and environmental feasibility

Power-to-gas technologies are considered to be part of the future energy system, but their viability and applicability need to be assessed. Therefore, models for the viability of farm-scale bio-power-to-methane supply chains to produce green gas were analysed in terms of levelised cost of energy, energy efficiency and saving of greenhouse gas emission. In bio-power-to-methane, hydrogen from electrolysis driven by surplus renewable electricity and carbon dioxide from biogas are converted to methane by microbes in an ex situ trickle-bed reactor. Such bio-methanation could replace the current upgrading of biogas to green gas with membrane technology. Four scenarios were compared: a reference scenario without bio-methanation (A), bio-methanation (B), bio-methanation combined with membrane upgrading (C) and the latter with use of renewable energy only (all-green; D). The reference scenario (A) has the lowest costs for green gas production, but the bio-methanation scenarios (B-D) have higher energy efficiencies and environmental benefits. The higher costs of the bio-methanation scenarios are largely due to electrolysis, whereas the environmental benefits are due to the use of renewable electricity. Only the all-green scenario (D) meets the 2026 EU goal of 80% reduction of greenhouse gas emissions, but it would require a CO2 price of 200 € t−1 to achieve the levelised cost of energy of 65 €ct Nm−3 of the reference scenario. Inclusion of the intermittency of renewable energy in the scenarios substantially increases the costs. Further greening of the bio-methanation supply chain and how intermittency is best taken into account need further investigation.</p

Multivariate comparison of taxonomic, chemical and operational data from 80 different full-scale anaerobic digester-related systems

Abstract Background The holistic characterization of different microbiomes in anaerobic digestion (AD) systems can contribute to a better understanding of these systems and provide starting points for bioengineering. The present study investigates the microbiome of 80 European full-scale AD systems. Operational, chemical and taxonomic data were thoroughly collected, analysed and correlated to identify the main drivers of AD processes. Results The present study describes chemical and operational parameters for a broad spectrum of different AD systems. With this data, Spearman correlation and differential abundance analyses were applied to narrow down the role of the individual microorganisms detected. The authors succeeded in further limiting the number of microorganisms in the core microbiome for a broad range of AD systems. Based on 16S rRNA gene amplicon sequencing, MBA03, Proteiniphilum, a member of the family Dethiobacteraceae, the genus Caldicoprobacter and the methanogen Methanosarcina were the most prevalent and abundant organisms identified in all digesters analysed. High ratios for Methanoculleus are often described for agricultural co-digesters. Therefore, it is remarkable that Methanosarcina was surprisingly high in several digesters reaching ratios up to 47.2%. The various statistical analyses revealed that the microorganisms grouped according to different patterns. A purely taxonomic correlation enabled a distinction between an acetoclastic cluster and a hydrogenotrophic one. However, in the multivariate analysis with chemical parameters, the main clusters corresponded to hydrolytic and acidogenic microorganisms, with SAOB bacteria being particularly important in the second group. Including operational parameters resulted in digester-type specific grouping of microbes. Those with separate acidification stood out among the many reactor types due to their unexpected behaviour. Despite maximizing the organic loading rate in the hydrolytic pretreatments, these stages turned into extremely robust methane production units. Conclusions From 80 different AD systems, one of the most holistic data sets is provided. A very distinct formation of microbial clusters was discovered, depending on whether taxonomic, chemical or operational parameters were combined. The microorganisms in the individual clusters were strongly dependent on the respective reference parameters. Graphical Abstrac

IMI - Clinical Management Guidelines Report

Best practice clinical guidelines for myopia control involve an understanding of the epidemiology of myopia, risk factors, visual environment interventions, and optical and pharmacologic treatments, as well as skills to translate the risks and benefits of a given myopia control treatment into lay language for both the patient and their parent or caregiver. This report details evidence-based best practice management of the pre-, stable, and the progressing myope, including risk factor identification, examination, selection of treatment strategies, and guidelines for ongoing management. Practitioner considerations such as informed consent, prescribing off-label treatment, and guides for patient and parent communication are detailed. The future research directions of myopia interventions and treatments are discussed, along with the provision of clinical references, resources, and recommendations for continuing professional education in this growing area of clinical practice